FMP

FMP

Enter

Verona Pharma plc (NASDAQ:VRNA) Financial Efficiency Analysis

-

twitterlinkedinfacebook
blog post cover photo

Image credit: Google Images

Verona Pharma plc (NASDAQ:VRNA) is a pharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases. The company is primarily engaged in the research and development of treatments for conditions such as chronic obstructive pulmonary disease (COPD) and asthma. In the competitive landscape, Verona Pharma's peers include companies like Immuron Limited, Rhythm Pharmaceuticals, Milestone Pharmaceuticals, Akero Therapeutics, and Mersana Therapeutics.

In evaluating Verona Pharma's financial efficiency, the Return on Invested Capital (ROIC) is a critical metric. Verona Pharma's ROIC stands at -37.67%, which is significantly lower than its Weighted Average Cost of Capital (WACC) of 5.93%. This results in a ROIC to WACC ratio of -6.35, indicating that the company is not generating sufficient returns to cover its cost of capital.

Comparatively, Immuron Limited (IMRN) shows a ROIC of -46.07% against a WACC of 10.83%, resulting in a ROIC to WACC ratio of -4.26. Despite having a negative ROIC, Immuron is relatively more efficient than Verona Pharma in generating returns compared to its cost of capital. This suggests that Immuron is managing its investments more effectively in the current market environment.

Rhythm Pharmaceuticals (RYTM) and Milestone Pharmaceuticals (MIST) also exhibit negative ROIC values of -96.06% and -55.81%, respectively. Their WACC figures are 15.48% and 9.62%, leading to ROIC to WACC ratios of -6.20 and -5.80. While these ratios are negative, they highlight the challenges these companies face in achieving profitability, similar to Verona Pharma.

Akero Therapeutics (AKRO) and Mersana Therapeutics (MRSN) have ROIC to WACC ratios of -7.32 and -4.27, respectively. Akero's ROIC of -36.27% against a WACC of 4.95% suggests a struggle in generating returns, while Mersana's ROIC of -60.07% and WACC of 14.05% indicate similar challenges. These comparisons underscore the broader industry trend of high costs relative to returns, affecting Verona Pharma and its peers.

Other Blogs

May 27, 2024 3:30 PM - Rajnish Katharotiya

The best 5 GPU stocks other than NVDA

In the ever-evolving world of technology, certain sectors have consistently demonstrated exceptional growth and innovation. The graphics processing units (GPUs) industry is one such sector, offering investors a golden opportunity for potentially high returns. In this blog, we'll delve into why inves...

blog post title

Jun 10, 2024 3:46 AM - Parth Sanghvi

Fixed Costs vs Variable Costs: Understanding Cost Structures

Understanding the difference between fixed and variable costs is essential for managing a business’s finances. These costs form the foundation of any cost structure and play a critical role in pricing, budgeting, and profit margin analysis. In this guide, we will explore what fixed and variable cost...

blog post title

Jul 10, 2024 2:34 AM - Parth Sanghvi

Capital Budgeting Techniques: NPV, IRR, and More - A Comprehensive Guide

Capital budgeting is a critical financial process that companies use to evaluate and select long-term investments or projects. It involves assessing potential expenditures and determining their profitability to ensure that resources are allocated effectively. This comprehensive guide covers essentia...

blog post title
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedin
2017-2024 © Financial Modeling Prep